Budesonide orodispersible tablets maintain EoE remission

SAN DIEGO — Patients receiving budesonide orodispersible tablets for the treatment of eosinophilic esophagitis were able to maintain remission through 48 weeks, according to study results presented at Digestive Disease Week.
Alfredo Lucendo, MD, of the department of gastroenterology at Hospital General de Tomelloso in Spain, said previous studies have shown that budesonide orodispersible tablets (BOT) induce remission in patients with EoE.
“This maintenance of remission trial had the primary goal to assess the efficacy of two doses of this novel formulation of budesonide compared to

Source link

Related posts

Global Aid Programs Shortchange Teen Health Needs: Study


High-Fat Diets Do No Favors for Your Gut Bacteria


The outcomes of bariatric surgery on rheumatoid arthritis disease activity: a prospective cohort study


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy